TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24241787
Drug: Both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both agents (Tamoxifen and Fenretinide)
Study: 21178084
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d of algal DHA
Study: 16921042
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no additional chemotherapy)
Study: 1758414
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration therapy using a resorbable membrane
Study: 1758414
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration therapy using a nonresorbable membrane
Study: 7045255
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% acyclovir (ACV) in polyethylene glycol (PEG)
Study: 27154976
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion plus standardized protocol of peroneal nerve electrostimulation (1 Hz frequency, 27 mA current, 200 ms pulse width)
Study: 27154976
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion protocol alone
Study: 27154976
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Iloprost infusion alone and Iloprost infusion plus electrostimulation)
Study: 26370136
Drug: Aclidinium (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium (400 μg, bd)
Study: 14685870
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (0.3 g/kg per day)
Study: 11986017
Drug: Active mechanical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active mechanical massage by intermittent negative pressure on the abdominal wall (Cellu M50 device, LPG, Valence, France); performed daily until the seventh postoperative day.
Study: 11986017
Drug: Active mechanical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active mechanical massage group; performed daily until the seventh postoperative day.
Study: 9876753
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment (ondansetron or metoclopramide) in males
Study: 8541815
Drug: Ambroxol, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol, 150 mg.day‐1
Study: 2121104
Drug: 0.01 mg
Normalized name: urea 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg of recombinant human IFN‐gamma
Study: 2121104
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg of recombinant human IFN‐gamma
Study: 750151
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of hyperosmotic solutions made with glycerol
Study: 31264085
Drug: Biophysical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biophysical therapy (electromagnetic information transfer through aqueous system procedure every 3 months)
Study: 31264085
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment with renin‐angiotensin‐aldosterone system inhibitors)
Study: 29405515
Drug: BCG-PSN therapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-PSN therapy (intradermal injections, twice weekly for three weeks)
Study: 24796339
Drug: Delcasertib 50
Normalized name: Delcasertib
DrugBank: Delcasertib (DB05560)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delcasertib 50 mg/h
Study: 24796339
Drug: Delcasertib 150
Normalized name: Delcasertib
DrugBank: Delcasertib (DB05560)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delcasertib 150 mg/h
Study: 24796339
Drug: Delcasertib 450
Normalized name: Delcasertib
DrugBank: Delcasertib (DB05560)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delcasertib 450 mg/h
Study: 17663098
Drug: Scalp-acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp-acupuncture plus body-acupuncture combined with body therapy and performance therapy
Study: 17663098
Drug: Simple body
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple body therapy and performance therapy
Study: 10409573
Drug: Dexamethasone (Dex)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (Dex) treatment at doses of 0.5 mg and 1.5 mg administered twice daily for 4.5 days
Study: 6994477
Drug: Narcotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic medications
Study: 31643039
Drug: Prasugrel 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 2.5 mg
Study: 31643039
Drug: Prasugrel 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 7.5 mg
Study: 31643039
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg and 7.5 mg (CYP2C19 intermediate metabolizers)
Study: 25812823
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg daily for 7 days)
Study: 17720079
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of triamcinolone acetonide (4 mg/0.1 mL)
Study: 17720079
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (steroid group)
Study: 15155466
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) monotherapy (serum concentrations 346‐693 microM [50‐100 microg/mL])
Study: 15155466
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) + all-trans retinoic acid (ATRA) (80 mg/m(2)/d, days 1‐7, every other week)
Study: 11559644
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 or 40 mg daily)
Study: 3312553
Drug: Heparin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (low doses)
Study: 31444663
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy ± red blood cell transfusion
Study: 26582873
Drug: MMRII co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRII co-administered with HAV, VAR, and PCV7
Study: 19339045
Drug: Polycap (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycap (low doses of thiazide 12.5 mg, atenolol 50 mg, ramipril 5 mg, simvastatin 20 mg, and aspirin 100 mg per day)
Study: 16987908
Drug: Epoetin-beta (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-beta (all dosage groups)
Study: 12810937
Drug: Valdecoxib 20
Normalized name: valdecoxib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 20 mg daily
Study: 12810937
Drug: Valdecoxib 40
Normalized name: valdecoxib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 40 mg daily
Study: 12810937
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg slow release twice daily
Study: 29950182
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g single dose, administered 1 day before surgery)
Study: 29950182
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single dose, administered 1 day before surgery)
Study: 22155918
Drug: HIV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV RNA >5 log(10) copies/ml
Study: 19109315
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for non-specific low back pain
Study: 19109315
Drug: Treatments with
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments with large effects (>20 points)
Study: 17890232
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart twice daily
Study: 11682378
Drug: Esmolol (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (105 g x kg(‐1) x min(‐1)) and Nitroglycerin (1‐6 mg/h)
Study: 29395965
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg emedastine patch
Study: 29395965
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg emedastine patch
Study: 29395965
Drug: Levocetirizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (5 mg tablet)
Study: 25372846
Drug: Risperidone or
Normalized name: risperidone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone or aripiprazole (12 weeks treatment)
Study: 9312922
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFA) 5.2 g daily for 12 weeks
Study: 8513986
Drug: Metoclopramide with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide with fluoxetine
Study: 2880066
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 500 mg, three times a day for 10 days
Study: 2880066
Drug: Intravenous azlocillin
Normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous azlocillin 5 g and gentamicin 80 mg, three times a day for 10 days
Study: 14656276
Drug: TEC (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEC (paclitaxel 175 mg/m2, carboplatin AUC 5, epirubicin 75 mg/m2)
Study: 14656276
Drug: TC (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC (paclitaxel 175 mg/m2, carboplatin AUC 5)
Study: 8402762
Drug: Celiprolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (300 mg/day)
Study: 31960175
Drug: Exposure-based SAD-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based SAD-specific group cognitive behavioral therapy (CBT), n=31
Study: 29502984
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg once daily at bedtime
Study: 15984576
Drug: Beta-adrenoblockers (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoblockers (administered in both groups)
Study: 12753444
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of morphine (40 micro g x kg‐1 initial bolus, 10 micro g.ml‐1 infusion)
Study: 12753444
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of clonidine (1 micro g x kg‐1 initial bolus, 0.6 micro g.ml‐1 infusion)
Study: 10069510
Drug: Tiotropium (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (once daily inhalation for 28 days)
Study: 8913544
Drug: Losartan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan with low-dose hydrochlorothiazide
Study: 6298934
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of cotrimoxazole
Study: 6298934
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of amoxycillin
Study: 6298934
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of Na-bicarbonate
Study: 30203839
Drug: Siltuximab (anti-IL6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab (anti-IL6 monoclonal antibody)
Study: 23336746
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream (0.05%) and Aloe vera topical gel (50%)
Study: 23336746
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream (0.05%) and vehicle
Study: 20938821
Drug: Open operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open operative reflux therapy
Study: 18547426
Drug: Choline-stabilized orthosilicic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 6 mg Si
Study: 18547426
Drug: Choline-stabilized orthosilicic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 12 mg Si
Study: 18547426
Drug: Choline-stabilized orthosilicic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 3 mg Si
Study: 18547426
Drug: Choline-stabilized orthosilicic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 6 mg Si (subgroup analysis)
Study: 15947831
Drug: 10% polyvinylpyrrolidone-iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% polyvinylpyrrolidone-iodine solution
Study: 15947831
Drug: 0.9% physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% physiological saline solution
Study: 12199971
Drug: Pressurized metered-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized metered-dose inhalers (MDIs)
Study: 10424324
Drug: Loperamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4 mg at -24, -12 h and -1 h)
Study: 10424324
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg q.i.d, first dose 3 days before study)
Study: 8524984
Drug: ipsapirone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone (0.3 mg per kg body weight)
Study: 2273527
Drug: Nicotine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (1.0 mg FTC‐estimated nicotine delivery)
Study: 7006783
Drug: Different types
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different types of therapy for five types of glomerulonephritis (specific therapies not detailed in the abstract)
Study: 31879033
Drug: SYDNEY device
Normalized name: Sydney golden wattle pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYDNEY device (1 × 300 mg injection)
Study: 31879033
Drug: Currently approved
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Currently approved autoinjector (2 × 150 mg injections)
Study: 20934265
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment (CMT) using radiotherapy (RT), infusional 5‐fluorouracil, and mitomycin C
Study: 20934265
Drug: Iridium-192 implant
Normalized name: iridium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iridium-192 implant boost (25 Gy)
Study: 15188832
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg danazol three times daily for 6 months
Study: 15188832
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg leuprorelin acetate depot every 28 days for 6 months
Study: 8110557
Drug: dobutamine 10
Normalized name: DOBUTamine 1000 MG in 250 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: dobutamine 10 micrograms kg‐1 min‐1 before discontinuation of CPB
Study: 8110557
Drug: enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoximone 0.5 mg kg‐1 followed by an infusion of 10 micrograms kg‐1 min‐1 before discontinuation of CPB
Study: 28320794
Drug: Community health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community health volunteers (CHVs) offering free rapid diagnostic tests (RDTs) and vouchers for WHO-qualified artemisinin combination therapy (ACT) at a reduced price.
Study: 23551657
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg twice a day for 14 days)
Study: 23551657
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard medical treatment for ICH)
Study: 21450118
Drug: 4 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 × 240 ml black tea providing 168 mg of caffeine
Study: 21450118
Drug: 6 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 × 240 ml black tea providing 252 mg of caffeine
Study: 17473069
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose L‐T4 (subclinical hypothyroid arm)
Study: 17473069
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose L‐T4 (euthyroid arm)
Study: 9677446
Drug: Pre-operative radiation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative radiation therapy followed by cystectomy
Study: 7932278
Drug: Alprazolam treatment
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam treatment over 8 weeks
Study: 29024081
Drug: Rosa canina
Normalized name: ROSA CANINA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosa canina fruit capsules (500 mg, twice daily for 20 days)
Study: 27138026
Drug: Reference tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference tablets (coadministered commercially available amlodipine and rosuvastatin)
Study: 15844319
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) injection (10 microg/d for 10 days in one month, for a total of 6 months)
Study: 15844319
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) injection
Study: 15844319
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PGE1, same other therapy)
Study: 10403876
Drug: Cerebral palsy
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral palsy not taking anticonvulsant medication
Study: 10403876
Drug: Cerebral palsy
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral palsy taking anticonvulsant medication
Study: 2160343
Drug: Low sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium, cholesterol lowering diet (less than 60 mmol/day sodium, 30% energy from fat, high P/S ratio, 30-50 g/day fibre)
Study: 2160343
Drug: Sodium supplement
Normalized name: Sodium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium supplement (100 mmol/day NaCl)
Study: 29986150
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of MCT alone (30 g·day‐1)
Study: 29021908
Drug: Fustra20Neck&Back exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fustra20Neck&Back exercise program, individually guided neuromuscular exercise twice weekly for 10 weeks
Study: 25546379
Drug: Low-dose active
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose active (LDA) group: 500 mg of flaxseed hull extract containing 100 mg of secoisolariciresinol diglucoside (SDG), n=26
Study: 25546379
Drug: High-dose active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose active (HDA) group: 1000 mg of flaxseed hull extract containing 200 mg of secoisolariciresinol diglucoside (SDG), n=26
Study: 25546379
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) group: matching maltodextrin capsules, n=28
Study: 21301382
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (1.25 mg/0.05 mL) every 4 weeks
Study: 2635350
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (ABM) 1.5 mg.kg-1
Study: 2635350
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (ABM) 2.25 mg.kg-1
Study: 2635350
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (ABM) 0.75 mg.kg-1
Study: 370525
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg per day) during the luteal phase
Study: 30866856
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA‐α) injection (0.45 μg/kg once weekly subcutaneously)
Study: 30866856
Drug: EPO (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO (50 IU/kg thrice weekly subcutaneously)
Study: 28100192
Drug: Other basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other basal insulin regimens
Study: 27190323
Drug: Emapticap (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emapticap (0.5 mg/kg)
Study: 17966757
Drug: Amiodarone 200
Normalized name: amiodarone 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 200 mg tablet with food
Study: 17966757
Drug: Amiodarone 200
Normalized name: amiodarone 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 200 mg tablet without food
Study: 14588350
Drug: Nonoperative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative management (spinal extensor muscle-strengthening exercise, medications, and restricted duty)
Study: 7512336
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment for AMD
Study: 7512336
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment for ocular histoplasmosis
Study: 7512336
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment for idiopathic choroidal neovascularization
Study: 7512336
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment for normotensive patients with AMD
Study: 7512336
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment for hypertensive patients with AMD
Study: 2974719
Drug: 5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl peroxide gel (Benzac W5)
Study: 2974719
Drug: 1% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin phosphate solution (Cleocin T)
Study: 26168743
Drug: Methocarbamol (Ortoton),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methocarbamol (Ortoton), orally administered for up to 8 days